Publikationer - TAT
Här finns avhandlingar, uppsatser och viktiga publikationer som gjort av forskare från TAT-gruppen
Viktiga vetenskapliga artiklar
Swedish Cancer Foundation
An article on the TAT groups work with targeted alpha therapy of ovarian cancer, brought about the fellowship awarded to Emma Aneheim during 2019 by the same foundation. In Swedish "Konstgjort grundämne ska stråla sönder cancer i äggstockarna"
Science Spotlight - Fred Hutch News
The Fred Hutchinson Cancer Research Center published a popular science news article on their web-page "Fine-tuning radioimmunotherapy with an alpha-emitting radionuclide" in April 15, 2013, concerning a collaborative work with Tom Bäck.
Research Media
Innovative immunotherapy. Lars Jacobsson and Ragnar Hultborn. International Innovation, May 2012, (Research Media, UK, pp 114-116).
Onkologi i Sverige
Konform strålterapi på cellnivå med alfaradioligander. The article (in Swedish) is found via the link below. The article was published in the 5th issue at pages 66-71, 2011.
Dagens Medicin
A summary of the article (in Swedish) is found via the link below. The whole article was published on the 7th of June, 2007.
Forskning & Framsteg
A summary of the article (in Swedish) is found via the link below. The whole article was published in number 8 of the journal, 2007.
If you would like to read it, please Click here!
Göteborgs-Posten
A summary of the article (in Swedish) is found via the link below. The whole article was published on the 1st of March, 2005.
Doktorsavhandlingar
Anna Gustafsson-Lutz, Chemist.
Development of targeted alpha therapy with Bi-213 and At-211 for the treatment of disseminated cancer - Synthesis and evaluation of pretargeting components and radioimmunoconjugates. Institute of Clinical Sciences. Sahlgrenska Academy, University of Gothenburg. 2016.
Elin Cederkrantz, Physicist.
Pharmacokinetics and dosimetry in intraperitoneal radioimmunotherapy with At-211. Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg. 2014.
Karin Magnander, Physicist.
Formation and Repair of Complex DNA Damage Induced by Ionizing Radiation Institute of Clinical Sciences. Sahlgrenska Academy. University of Gothenburg. 2013.
Sofia Frost, Chemist.
Pretargeting agents and 211At-labeled effector molecules. Synthesis and preclinical evaluation for pretargeted alpha-radioimmunotherapy. Institute of Clinical Sciences. Sahlgrenska Academy. University of Gothenburg. 2012. See thesis.
Kristina Claesson, Physicist.
Radiobiological effects of alpha-particles from Astatine-211. From DNA damage to cell death. Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg. 2011.
Tom Bäck, Biomedical Scientist.
Alpha-radioimmunotherapy with At-211. Evaluation and imaging of normal tissues and tumors.
Institute of Clinical Sciences, Sahlgrenska Academy. University of Gothenburg. 2011.
Jörgen Elgqvist, Physicist.
Astatine-211 radioimmunotherapy of ovarian cancer – therapeutic efficacy, myelotoxicity, and radiation dosimetry in an animal model. Institute of Clinical Sciences, Sahlgrenska Academy. University of Gothenburg. 2006.
Sture Lindegren, Chemist.
Astatine-211 and iodine conjugates: Radiohalogenation and preclinical pharmacokinetics for targeted and pretargeted radioimmunotherapy, Department of Nuclear Chemistry, Chalmers University of Technology 2002.
Håkan Andersson, Physician.
Radioimmunotherapy of experimental ovarian cancer with astatine-211 – a model for consolidation treatment in women. Department of Oncology, University of Gothenburg, 2000.
Stig Palm, Physicist.
In vitro effects and microdosimetry of astatine-211 for tumour therapy. Institute of Clinical Sciences. Sahlgrenska Academy, University of Gothenburg. 1999.
MSc uppsatser
19. Johan Almblad
Pretargeted radioimmunotherapy using the inverse diels alder addition between tetrazine and trans-cyclooctene Supervisor: Sture Lindegren, Emma Aneheim, 2017.
18. John Apelman
Production of an Avidin Conjugated Antibody Pretargeting Agent Supervisor: Sture Lindegren, Emma Aneheim, 2015.
17. Tierra Duffield
Synthesis and Quality Control of Radiohalogenated PSMA Inhibitors for Targeted Therapy of Prostate Cancer Supervisor: Sture Lindegren, Emma Aneheim, 2015.
16. David Wadsten
Fc-gammaR in Alpha-radioimmunotherapy: Work up of a head to head in vivo comparison of F(ab)2 fragments with intact IgG MX35 Supervisor: Per Albertsson, 2013.
15. Besart Rexhaj
Initial development of voxel dose kernel dosimetry in MATLAB for alpha particles using Alpha Camera imaging of tissue samples Supervisors: Tom Bäck and Stig Palm, 2013.
14. Jenny Halleröd
Shelf life of "epsilon-Lysyl-3-(Trimethylstannyl) Benzamide Immunoconjugates and Poly-L-Lysine Conjugates. Supervisor: Sture Lindegren, Emma Aneheim, 2013.
13. Johnny Kallin
Development of a dosimetric model for alpha-particle irradiation with 213Bi and an in vitro experiment to assess complex DNA damage in human diploid fibroblasts. Supervisors: Kecke Elmroth, Karin Magnander, and Jörgen Elgqvist, 2011.
12. Daniela Markoscan
Evaluation of Ligand Tracer Grey Instrument. Supervisor: Sture Lindegren, 2009.
11. Emil Boström
125I-labelling of TRP-receptor ligand for prostate cancer therapy. Supervisor: Sture Lindegren, 2008.
10. Jens Zimmerman
Activity determination of the alpha-emitting radionuclide 225Ac. Supervisor: Stig Palm, 2007.
9. Sofia Frost
Synthesis and evaluation of pretargeting and effector molecules for pretargeted radioimmunotherapy. Supervisor: Sture Lindegren, 2006.
8. Maria Ohlsson
Optimising a method for visualising gammaH2AX-foci after irradiation with X-ray and Astatine-211. Supervisors: Kecke Elmroth and Lars Jacobsson, 2006.
7. Karin Magnander
The use of pulsed field gel electrophoresis, measuring double-strand breaks and clustered damage after exposure to ionizing radiation of different beam qualities. Supervisors: Kecke Elmroth and Lars Jacobsson, 2005.
6. Leif Jonasson
A study of the binding kinetics of MX-35 on OVCAR-3 cancer cells using 211At. Supervisors: Gunnar Skarnemark and Lars Jacobsson, 2003.
5. Jonas Häller
A study of the antibody MX-35 labeled with 211At on OVCAR-3 cells for cancer therapy. Supervisors: Gunnar Skarnemark, Lars Jacobsson and Allan Emrén, 2003.
4. Kristina Claesson
Distribution and quantification of DNA double-strand breaks in a human cells irradiated with X-rays and alpha-particles from 211At. Supervisor: Kecke Elmroth, 2003.
3. Lisa Hansson
Binding kinetics of 125I labeled monoclonal antibodies evaluated in vitro with a radiation detector system. Supervisor: Lars Jacobsson, 2002.
2. Karin Bengtsson
Utvärdering av internalisering av radioaktivt märkta antikroppar och av antikroppar i pretargetingsystem. Supervisor: Sture Lindegren, 2000.
1. Charlotta Johansson
Activity measurements of 211At Supervisor: Lars Jacobsson, 1999.
Artiklar, böcker och kapitel 2016-2020
2020
84. Lindegren S, Albertsson P, Bäck T, Jensen H, Palm S, Aneheim E.Realizing Clinical Trials With Astatine-211: The Chemistry Infrastructure. Cancer Biotherapy and Radiopharmaceuticals 2020;35(2)
2019
83. Aneheim E, Palm S, Jensen H, Ekberg C, Albertsson P, Lindegren S. Towards elucidating the radiochemistry of astatine – Behavior in chloroform. Scientific Reports 2019;9;15900
82. Denk C, Wilkovitsch M, Aneheim E, Herth M, Jensen H, Lindegren S, Mikula H. Multifunctional clickable reagents for rapid bioorthogonal astatination and radio‐crosslinking. ChemPlusChem 2019;84: 775–778
81. Dekempeneer Y, Bäck T, Aneheim E, Jensen H, Puttemans J, Xavier C, Keyaerts M, Palm S, Albertsson P, Lahoutte T, Caveliers V, Lindegren S, D'Huyvetter M, Labeling of anti-HER2 nanobodies with astatine-211: Optimization and the effect of different coupling reagents on their in vivo behaviour. Mol Pharmaceutics, 2019;16:3524-3533
80. Hallqvist A, Bergmark K, Bäck T, Andersson H, Dahm-Kähler P, Johansson M, Lindegren S, Jensen H, Jacobsson L, Hultborn R, Palm S, Albertsson P. Intraperitoneal alpha-emitting radio immunotherapy with Astatine-211 in relapsed ovarian cancer; long-term follow-up with individual absorbed dose estimations. J Nucl Med, 2019;60(8):1073-1079
2018
79. Palm S, Bäck T, Lindegren S, Hultborn R, Jacobsson L, Albertsson P. Model of Intraperitoneal Targeted α-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes. J Nucl Med, 2018; 59:646–651
2017
78. Gustafsson-Lutz A, Bäck T, Aneheim E, Hultborn R, Palm S, Jacobsson L, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model. EJNMMI Research, 2017; 7:38
77. Bäck T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, Palm S. Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated α-Radioimmunotherapy with 211At-MX35-F(ab′)2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival J Nucl Med, 2017; 58:598-604
76. Levan K, Mehryar M, Mateoiu C, Albertsson P, Bäck T, Sundfeldt K.
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b. BMC Cancer, 2017;17:303
75. Gustafsson-Lutz A, Bäck T, Aneheim A, Palm S, Morgenstern A, Bruchertseifer F, Albertsson P, Lindegren S. Biotinylated and Chelated Poly-L-Lysine as Effector for Pretargeting in Cancer Therapy and Imaging. Int J Pharm Pharm Sci, 2017; 9(1):87-93
2016
74. Aneheim E, Gustafsson A, Albertsson P, Bäck T, Jensen H, Palm S, Svedhem S, Lindegren S. Synthesis and Evaluation of Astatinated N‑[2-(Maleimido)ethyl]-3- (trimethylstannyl)benzamide Immunoconjugates.
73. Palm S, Bäck T, Haraldsson B, Jacobsson L, Lindegren S, Albertsson P. Biokinetic Modeling and Dosimetry for Optimizing Intraperitoneal Radioimmunotherapy of Ovarian Cancer Microtumors. J Nucl Med, 2016; 57(4):594-600
Artiklar, böcker och kapitel 1998-2015
2015
72. Frost S H, Miller B W, Bäck T A, Santos E B, Hamlin D K, Knoblaugh S E, Frayo S L, Kenoyer A L, Storb R, Press O W, Wilbur D S, Pagel J M, Sandmaier B M. α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation, J Nucl Med, 2015; 56(11):1766-1773
71. Cederkrantz E, Andersson H, Bernhardt P, Bäck T, Hultborn R, Jacobsson L, Jensen H, Lindegren S, Ljungberg M, Magnander T, Palm S, Albertsson P. Absorbed Doses and Risk Estimates of 211At-MX35 F(ab’)2 in Intraperitoneal Therapy of Ovarian Cancer Patients, Int J Radiation Oncol Biol Phys, 2015; 93 (3):569-576
70. Aneheim E, Albertsson P, Bäck T, Jensen H, Palm S, Lindegren S.
Automated astatination of biomolecules – a stepping stone towards multicenter clinical trials, Scientific Reports 2015;5:12025
69. Green J D, Shadman M, Jones J C, Frayo S L, Kenoyer A L, Hylarides M D, Hamlin D K, Wilbur S, Balkan E R, Lin Y, Miller B W, Frost S H L, Gopal A K, Orozco J J, Gooley T A, Laird K L, Till B G, Bäck T, Sandmaier B M, Pagel J M, Press O W. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, Blood. 2015; 125(13):2111-2119
68. Lindegren S, Andrade L N S, Bäck T, Machado C M L, Horta B B, Buchpiguel C, Moro A M, Okamoto O K, Jacobsson L, Cederkrantz E, Washiyama K, Aneheim E, Palm S, Jensen H, Tuma M C B, Chammas R, Hultborn R, Albertsson P. Binding Affinity, Specificity and comparative Biodistribution of the Parental Murine Monoclonal antibody MX35 (anti-NaPi2b) and its Humanized Version Rebmab200, PLOS ONE. 2015; DOI:10.1371/journal.pone.0126298
67. Aneheim E, Halleröd J, Albertsson P, Jensen H, Holgersson S, Lindegren S. Shelf-life of ϵ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, a precursor for 211At labeling of antibodies, Cancer Biother Radiopharm. 2015;30(1):41-45
66. Aneheim E, Foreman M, Jensen H, Lindegren S, N-[2-(maleimido)ethyl]-3-(trimethylstannyl)benzamide, a molecule for radiohalogenation of proteins and peptides, Appl Radiat Isot. 2015;96:1–5
65. Aneheim E, Jensen H, Albertsson P, Lindegren S. Astatine-211 labeling: a study towards automatic production of astatinated antibodies, J. Radioanal. Nucl. Chem. 2015;303(1):979-983
2014
64. Eriksson S. E, Elgström E, Bäck T, Ohlsson T, Jensen H, Nilsson R, Lindegren S, Tennvall J. Sequential Radioimmunotherapy with 177Lu and 211At-Labeled Monoclonal Antibody BR96 in a Syngeneic Rat Colon Carcinoma Model. Cancer Biother Radiopharm. 2014;29(6):1-9
63. Lindegren S, Jensen H, Jacobsson L. A radio-high-performance liquid chromatography dual-flow cell gamma-detection system for on-line radiochemical purity and labeling efficiency determination. J. Chromatogr. A. 2014;1337:128–132
62. Elgqvist J, Frost S, Pouget J-P, Albertsson P. The potential and hurdles of targeted alpha therapy – clinical trials and beyond. Front. Oncol. 14 Jan, 2014. doi: 10.3389/fonc.2013.00324
2013
61. Frost S H L, Santos E B, Miller B W, Bäck T A, Hamlin D K, Wilbur S, Kenoyer A L, Frayo S L, Press O W, Storb R, Sandmaier B M, Pagel J M. Anti-CD45 Monoclonal Antibody (MAb) Dose Optimization For Astatine-211 (211At)-Radioimmunotherapy (RIT) Of Relapsed Non-Hodgkin Lymphoma (NHL) In a Canine Model. Blood. 2013;122(21) 5139
60. Orozco JJ, Bäck T, Kenoyer A, Balkin ER, Hamlin DK, Wilbur DS, Fisher DR, Frayo SL, Hylarides MD, Green DJ, Gopal AK, Press OW, Pagel JM. Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model. Blood. 2013; 121(18): 3759-3767
59. Chouin N, Lindegren S, Frost S, Jensen H, Albertsson P, Hultborn R, Palm S, Jacobsson L, Bäck T. Ex vivo activity quantification at the cellular scale using the Alpha Camera-technique. J Nucl Med. 2013;54(8):1347-1353
58. Eriksson SE, Bäck T, Elgström E, Jensen H, Nilsson R, Lindegren S, Tennvall J. Successful radioimmunotherapy of established syngeneic rat colon carcinoma with 211At-mAb., EJNMMI Research 2013;3,23 doi:10.1186/2191-219X-3-23
57. Frost SH, Bäck T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, Jensen H, Albertsson P, Lindegren S. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 2013;28(2):108-114
56. Danielsson A, Claesson K, Parris TZ, Nemes S, Helou K, Elmroth K, Elgqvist J, Jensen H, Hultborn R. Differential gene expression in human fibroblasts after alpha-particle emitter 211At compared with 60Co irradiation. Int J Radiat Biol. 2013;89(4):250-258
2012
55. Choiun N, Lindegren S, Jensen H, Albertsson P, Bäck T. Quantification of activity by alpha-camera imaging and small-scale dosimetry within ovarian carcinoma micrometastases treated with targeted alpha therapy. Q J Nucl Med Mol Imaging. 2012;56:487-495
54. Magnander K and Elmroth K. Biological consequences of formation and repair of complex DNA damage. Cancer Lett. 2012;327(1-2):90-96
53. Cederkrantz E, Angenete E, Bäck T, Falk P, Haraldsson B, Ivarsson ML, Jensen H, Lindegren S, Hultborn R, Jacobsson L. Evaluation of effects on the peritoneum after intraperitoneal alpha-radioimmunotherapy with 211At. Cancer Biotherapy Radiopharm. 2012;27(6):353-364
52. Gustafsson A, Bäck T, Elgqvist J, Jacobsson L, Hultborn R, Albertsson P, Morgenstern A, Bruchertseifer F, Jensen H and Lindegren S. Comparison of therapeutic efficacy and biodistribution of 213Bi- and 211At-labeled monoclonal antibody MX35 in an ovarian cancer model. Nucl Med Biol. 2012;39(1):15-22
51. Elgqvist J, Lindegren S and Albertsson P. Intraperitoneal radionuclide therapy – Clinical and pre-clinical considerations. Book chapter in Ovarian Cancer - Book 2. Publisher: InTech. ISBN 978-953-307-810-6.
2011
50. Frost HLS, Bäck T, Choiun N, Jensen H, Hultborn R, Jacobsson L and Lindegren S. In vivo distribution of avidin-conjugated MX35 and 211At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal alpha-radioimmunotherapy. Cancer Biother Radiopharm. 2011;26(6):727-736
49. Pagel JM, Kenoyer AL, Bäck T, Hamlin DK, Wilbur DS, Fisher DR, Park SI, Frayo S, Axtman A, Orgun N, Orozco J, Shenoi J, Lin Y, Gopal AK, Green DJ, Appelbaum FR, Press OW. Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model. Blood. 2011;118(3):703-711
48. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, Elmroth K. RBE of alpha-particles from 211At for complex DNA damage and cell survival in relation to cell cycle position. Int J Radiat Biol. 2011;87(4):372-384
47. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part II
46. Palm S, Elgqvist J and Jacobsson L. Patient-specific alpha-particle dosimetry. Curr Radiopharm. 2011;4(4):329-335
45. Lindegren S and Frost S. Pretargeted radioimmunotherapy with alpha-particle emitting radionuclides. Curr Radiopharm. 2011;4(3):248-260
44. Chouin N and Bardies M. Alpha-particle microdosimetry. Curr Radiopharm. 2011;4(3):266-280
43. Olafsen T, Elgqvist J, and Wu A. Protein targeting constructs in alpha therapy. Curr Radiopharm. 2011;4(3):197-213
42. Elgqvist J. Editorial; The Magic-Bullet: Moving the concept towards reality - Part I. Curr Radiopharm. 2011;4(3):176
41. Claesson K, Magnander K, Kahu H, Lindegren S, Hultborn R, and Elmroth K. RBE of alpha-particles from At-211 for complex DNA damage and cell survival in relation to cell cycle position. Int J Radiat Biol. 2011;87:372-384
2010
40. Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, Kenoyer AL, Frayo S, Axtman A, Bäck T, Lin Y, Fisher DR, Gopal AK, Green DJ, Press OW. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010; 116(20):4231-4239
39. Magnander K, Hultborn R, Claesson K, and Elmroth K. Clustered DNA damage in irradiated human diploid fibroblasts: influence of chromatin organization. Radiat Res. 2010;173:272–282
38. Bäck T and Jacobsson L. The Alpha Camera: A quantitative CCD-based digital autoradiography technique for high resolution bioimaging of alpha particles ex-vivo. J Nucl Med. 2010;51:1616-1623
37. Sgouros G, Roeske J, McDevitt M, Palm S, Allen B, Fisher D, Brill A, Song H, Howell R, and Akabani G. MIRD Pamphlet No. 22: Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med. 2010;51;311-328
36. Elgqvist J, Ahlberg D, Andersson H, Jensen H, Johansson BR, Kahu H, Olsson M, and Lindegren S. Intraperitoneal alpha-radioimmunotherapy of advanced ovarian cancer in nude mice using different high specific activities. World J Oncology. 2010;1:101–110
35. Elgqvist J, Johansson BR, Partheen K, and Danielsson A. Tumor cure probability during alpha-RIT of ovarian cancer with different radiation sensitivity. Anticancer Res. 2010;30:2545–2551
34. Elgqvist J, Hultborn R, Lindegren S, and Palm S. Ovarian cancer: Background and clinical perspectives. Book chapter in Targeted Radionuclide Therapy. Lippincott Williams & Wilkins, 2010, Ed. Tod Speer. Chapter 29, pages 380–396. ISBN: 978-0-7818-9693-4.
33. Elgqvist J. Astatine-211 radioimmunotherapy of ovarian cancer – Therapeutic efficay, myelotoxocity and radiation dosimetry in an animal model. Book published at Lambert Academic Publishing in 2010. ISBN: 978-3-8383-1721-2.
32. Frost S, Jensen H, and Lindegren S. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule. Cancer. 2010;116:1101–1110
2009
31. Bäck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, and Jacobsson L. Glomerular filtration rate after alpha-radioimmunotherapy with 211At- MX35-F(ab´)2: A long-term study of renal function in nude mice. Cancer Biother Radiopharm. 2009;24:649–658
30. Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer. J Oncology. 2009; volume 2010, ID 394913
29. Elgqvist J, Andersson H, Haglund E, Jensen H, Kahu H, Lindegren S, Warnhammar E, and Hultborn R. Intraperitoneal alpha-radioimmunotherapy in mice using different specific activities. Cancer Biother Radiopharm. 2009;24:509–513
28. Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, and Hultborn R. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of 211At-MX35 F(ab´)2 – a phase I study. J Nucl Med. 2009;50:1153–1160
2008
27. Lindegren S, Frost S, Bäck T, Haglund E, Elgqvist J, and Jensen H. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate. J Nucl Med. 2008;49:1537–1545
2007
26. Claesson K, Stenerlöw B, Jacobsson L, and Elmroth K. Relative biological effectiveness of the alpha-particle emitter 211At for double-strand break induction in human fibroblasts. Radiat Res. 2007;167:312–318
25. Palm A, Bäck T, Claesson I, Danielsson A, Elgqvist J, Frost S, Hultborn R, Jensen H, Lindegren S, and Jacobsson L. Therapeutic efficacy of astatine-211–labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice. Int J Radiat Oncol Biol Phys. 2007;69:572–579
2006
24. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F(ab')2: therapeutic efficacy and myelotoxicity. Nucl Med Biol. 2006;33:1065–1072
23. Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. Int J Radiat Oncol Biol Phys. 2006;66:1228–1237
22. Elgqvist J, Andersson H, Back T, Claesson I, Hultborn R, Jensen H, Johansson BR, Lindegren S, Olsson M, Palm S, Warnhammar E, and Jacobsson L. Alpha-radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: Outcome related to measured tumor size and mean absorbed dose. J Nucl Med. 2006;47:1342–1350
2005
21. Elgqvist J, Andersson H, Back T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, and Jacobsson L. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with 211At-labeled monoclonal antibody MX35. J Nucl Med. 2005;46:1907–1915
20. Bäck T, Andersson H, Divgi CR, Hultborn R, Jensen H, Lindegren S, Palm S, and Jacobsson L. 211At Radioimmunotherapy of subcutaneous human ovarian cancer xenografts: Evaluation of relative biologic effectiveness of an alpha-emitter in vivo. J Nucl Med. 2005;46:2061–2067
19. Elgqvist J, Bernhardt P, Hultborn R, Karlsson B, Lindegren S, Warnhammar E, and Jacobsson L. Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice. J Nucl Med. 2005;46:464–471
2004
18. Palm S, Humm JL, Rundqvist R, and Jacobsson L. Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004;31:218–225.
17. Ballangrud A, Yang W, Palm S, Enmon R, Borchardt P, Pellegrini V, McDevitt M, Scheinberg D, and Sgouros G. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression. Clin Cancer Res. 2004;10:4489–4497
2003
16. Palm S, Enmon R Jr, Matei C, Kolbert K, Xu S, Zanzonico P, Finn R, Koutcher J, Larson S, and Sgouros G. Pharmacokinetics and biodistribution of 86Y-Trastuzumab for 90Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI. J Nucl Med. 2003;44:1148–1155
15. Andersson H, Elgqvist J, Horvath G, Hultborn R, Jacobsson L, Jensen H, Karlsson B, Lindegren S, and Palm S. Astatine-211 labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model. Clinical Cancer Res. 2003;9:3914–3921(S)
14. Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, and Skarnemark G. At-211 labelled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-Lysine as multicarriers. Clinical Cancer Res. 2003;9:3873–3879(S)
13. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Lindegren S, and Jacobsson L. Single-cell irradiation from At-211 labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention. Anticancer Res. 2003;23:1219–1222.
2002
12. Lindegren S, Andersson H, Jacobsson L, Back T, Skarnemark G, and Karlsson B. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy. Bioconjug Chem. 2002;13:502–509
2001
11. Lindegren S, Bäck T, and Jensen H. Dry-distillation of astatine-211 from irradiated bismuth targets: a time-saving procedure with high recovery yields. Appl Radiat Isot. 2001;55:157–160
10. Lindegren S, Andersson H, Bäck T, Jacobsson L, Karlsson B, and Skarnemark G. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl) benzoate. Nucl Med Biol. 2001;28:33–39
9. Andersson H, Palm S, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody Mov18 in nude mice with intraperitoneally growth of human ovarian cancer. Anticancer Res. 2001;21:409–412.
8. Palm S and Jacobsson L. Dosimetrical considerations in astatine-211 radioimmunotherapy in therapeutic applications of radiopharmaceuticals. Proceedings of an international seminar held in Hyderbad, India, 18–22 January, 1999. IAEA-Tecdoc 1228. International Atomic Energy Commission, Vienna, 2001;310–319.
2000
7. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Cell growth kinetics of two human cancer cell lines irradiated with astatine-211 and gamma-radiation. Anticancer Res. 2000;20:1807–1812.
6. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. The curative and palliative potential of the monoclonal antibody Mov18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts – a long term study. Acta Oncol. 2000;39:741–745
5. Palm S, Andersson H, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I and Lindegren S. In vitro effects of free 211At, 211At-albumin, and 211At-monoclonal antibody compared to external photon irradiation on two human cancer cell lines. Anticancer Res. 2000;20:1005–1012.
4. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Radioimmunotherapy of nude mice with intraperitoneally growing ovarian cancer xenograft utilizing 211At-labelled monoclonal antibody Mov18. Anticancer Res. 2000:20:459–462.
1999
3. Andersson H, Lindegren S, Bäck T, Jacobsson L, Leser G, and Horvath G. Biokinetics of the monoclonal antibodies Mov 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method of the iodogen method in nude mice with ovarian cancer xenografts. Acta Oncol. 1999;38:323–328
1998
2. Palm S, Bäck T, Claesson I, Delle U, Hultborn R, Jacobsson L, Köpf I, and Lindegren S. Effects of the alpha-particle emitter At-211 and low-dose-rate gamma-radiation on the human cell line Colo-205 as studied with a growth assay. Anticancer Res. 1998;18:1671–1676.
1. Lindegren S, Skarnemark G, Jacobsson L, and Karlsson B. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as a